Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
SAN DIEGO, May 02, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Chief Scientific Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston on Wednesday, May 9, 2018 at 10:40 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
